Evidence map›Paper›PMID 29067319›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)2017

African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials.

Yan Zhou, David Elashoff, Sarah Kremen, Edmond Teng, Jason Karlawish, Joshua D Grill

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Study partners' views on remuneration in longitudinal Alzheimer's disease research.Alzheimer's & dementia. Behavior & socioeconomics of aging · 2025
    Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Reasons for undergoing amyloid imaging among diverse enrollees in the A4 study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  20. Observational

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yan ZhouAmerican Board of Anesthesiology, Raleigh, NC, USA.
David ElashoffDepartment of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Sarah KremenDepartment of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Edmond TengDepartment of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Jason KarlawishDepartments of Medicine and Medical Ethics and Health Policy, Alzheimer's Disease Core Center, Penn Neurodegenerative Disease Ethics and Policy Program, University of Pennsylvania, Philadelphia, PA, USA.
Joshua D GrillDepartment of Psychiatry and Human Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.

Funding

UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 1991 to 2020
$35.1M
NIA NIH HHS P30 AG010124
6 · The paper itself

Abstract

introductionAlzheimer's disease (AD) incidence is disproportionately high in African Americans, yet, recruitment of this community to AD clinical trials is challenging.

methodsWe compared 47 African Americans and 78 whites in their willingness to enroll in a hypothetical preclinical AD trial and examined barriers and facilitators in their decision making.

resultsAfrican American race (OR = 0.45; 95% CI, 0.22-0.93) and score on the research attitude questionnaire (OR = 1.12; 95% CI, 1.04-1.22) were independently associated with willingness to participate. African Americans rated study risks, the requirement of a study partner, study procedures, the ratio of drug to placebo, and study location as more important factors in the decision whether to enroll than did whites. DISCUSSION: These results suggest that researchers will encounter challenges in recruiting African Americans to preclinical AD trials. Future research will be necessary to understand the optimal means to improve recruitment of underrepresented populations.

Indexed as

Clinical trialMinorityPreventionRaceRecruitment

Identifiers

PMID29067319
PMCPMC5651355

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.